Literature DB >> 8098948

Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer.

H R Haak1, A P van Seters, A J Moolenaar, G J Fleuren.   

Abstract

The presence of P-glycoprotein, associated with multiple drug resistance and present in the normal adrenal cortex, was studied in 15 cases of adrenocortical carcinoma. P-glycoprotein was found in eight tumours; no correlation was found with clinical presentation, steroid production or histological index. 10 patients received mitotane. Remarkably, 3 patients with P-glycoprotein-positive tumours achieved complete remission. On the other hand, 2 patients with P-glycoprotein-negative tumours showed progression of the disease despite mitotane treatment. These findings suggest that the expression of P-glycoprotein in adrenocortical carcinoma is not related to clinical manifestations, steroid production, histological index or response to mitotane therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098948     DOI: 10.1016/s0959-8049(05)80219-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

Review 1.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

2.  Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.

Authors:  Teresa Gagliano; Erica Gentilin; Katiuscia Benfini; Carmelina Di Pasquale; Martina Tassinari; Simona Falletta; Carlo Feo; Federico Tagliati; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2014-08-06       Impact factor: 3.633

3.  Morphonuclear characterization of drug resistance by means of digital cell-image analysis: an in vitro assessment.

Authors:  O Pauwels; R Kiss
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.